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Sir,
The emergence and spread of carbapenem-resistant Enter-
obacteriaceae (CRE) is one of the most challenging public health
issues today. Therefore, rapid and accurate detection of infec-
ted patients or carriers is mandatory to prevent outbreak
development. In their recent review, P. Savard and T.M. Perl
underlined the putative contribution of molecular techniques to
screen CRE carriers directly from clinical samples [1]. The
GenExpert® system (Cepheid, Sunnyvale, CA, USA) has
developed a real-time PCR technique with ready-to use car-
tridges. This molecular-based technique can be implemented as
a point-of-care test in clinical settings. Genetic tools that do not
require technical skill or expanded time consumption should be
preferred, in particular when they can be implemented within
24 h, like the GenExpert® technology.
Recently, using this platform, a test has been developed for
early detection of the clinically relevant blaKPC, blaIMP, blaVIM
and blaNDM carbapenemase genes and, if needed, directly from
rectal swabs (Xpert MDRO Assay) [2]. The panel of those
carbapenemase genes was recently expanded to include the
blaOxA-48 gene (Xpert Carb-R) (Carretto et al., 14th European
Congress of Clinical Microbiology and Infectious Diseases,
P1184). In Europe there has been rapid spread of CRE, with
OXA-48-producing bacteria becoming the most prevalent [3].
The OXA-48-like group comprises 11 variants (as of August
2014), and the corresponding producers exhibit variable resis-
tance patterns. Indeed some may be extended spectrum β-lac-
tamase producers and therefore resistant to expanded-spectrum
cephalosporins, while others may be of reduced susceptibility or
resistant to carbapenems [4]. In addition several OXA-48-like
β-lactamases possess speciﬁc hydrolytic properties [4], such as
OXA-163 (differing from OXA-48 by a single amino acid sub-
stitution and a four amino acid deletion) conferring resistance to
broad-spectrum cephalosporins but hydrolysing carbapenems
only marginally. That makes the suspicion and detection of OXA-
48-like producers sometimes really difﬁcult. Recently EUCAST
has lowered the carbapenem screening cut-off to detect
carbapenemase-producing bacteria with moderately elevated
MICs (http://www.eucast.org/resistance_mechanisms).
Among the OXA-48 variants, OXA-181 differs from OXA-
48 by four amino acids but possesses very similar hydrolytic
activity toward β-lactams [5]. The blaOxA-181 gene was originally
identiﬁed from a Klebsiella pneumoniae isolate recovered in the
Sultanate of Oman and then in other enterobacterial species in
different geographical area, including UK, New Zealand,
Singapore, Australia, Canada, France, Norway, Sri Lanka and
Romania; the source of contamination being of Indian origin in
most cases [4,5]. In South Africa, OXA-181 is the most prev-
alent carbapenemase and in Singapore, OXA-181 is now
considered to be signiﬁcantly established. Recent data from the
French National Reference Center for Antibiotic Resistance in
2013 identiﬁed 11 OXA-181 producers out of 636 carbape-
nemase producers (P. Nordmann, personal communication).
Here we report failures in detecting a blaOxA-48-like gene in
Escherichia coli using a molecular technique. On 11 May 2014, a
69-year-old patient was admitted to the medical intensive care
unit (ICU) of a tertiary-care university hospital in a Paris suburb
(Henri Mondor Hospital) for acute pulmonary oedema. During
the previous month the patient had been hospitalized for
pneumonia in an ICU in the Comoro Islands (Africa). Rectal
screening was performed at hospital admission to screen for
multidrug-resistant organisms. It yielded (i) a negative signal
using the Xpert Carb-R® cartridge and (ii) two different mor-
photypes of E. coli (Ecol1 and Ecol2) from a concomitant culture
performed on selective screening medium (ChromID® OXA-
48; bioMérieux, Craponne, France). On 26 May 2014, another
patient (65 years old) consulted at the emergency ward of our
hospital for the management of a chronic end-stage renal failure.
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He was returning from Cambodia where he had been dialysed
several times. Although leading to a negative signal from the
Xpert Carb-R® cartridge, his rectal swabbing yielded an E. coli
isolate (Ecol3) also after culture onto selective media for CRE.
The three E. coli isolates were subsequently investigated.
According to the manufacturer’s recommendations, the negative
results of the molecular screening using rectal swabs were
conﬁrmed by performing the test directly on bacterial cultures
(Table 1). Antimicrobial susceptibility testingwas performed using a
disk diffusion method according to EUCAST guidelines (http://
www.eucast.org) and MICs of carbapenem were determined by
the Etest® method (bioMérieux). Finally, the Carba NP® test was
performed as previously described on cultured bacteria. The three
isolates exhibited different antimicrobial susceptibility patterns
including a low-level ertapenemresistance andapositiveCarbaNP®
test (Table 1). The three E. coli isolates were genetically unrelated
according to the results of rapid ampliﬁed polymorphic DNA
protocol (data not shown). In-house PCR to detect carbapenemase
genes followed by sequencing was performed as described [5]. It
showed that they were all positive for blaOxA-48-like genes and
sequencing identiﬁed the blaOxA-181 gene in all three isolates.
The lack of detection of OXA-181-producing isolates con-
stitutes here a pitfall for the implementation of a molecular
genetic approach as a ﬁrst screening test for detecting CRE.
Although OXA-181 differs from OXA-48 by only four amino
acid substitutions [6], the corresponding genes differ by 43 out
of 798 bp. This might explain the lack of ampliﬁcation and/or
detection by the Xpert® technique. Although OXA-181 pro-
ducers were initially mainly identiﬁed from India, here the two
cases originated from other geographical areas (Africa and
South-East Asia). This suggests that the prevalence of OXA-181
producers is certainly underestimated. The exact prevalence of
the blaOxA-181 gene remains unknown because molecular
identiﬁcation of the blaOxA-48 gene is not always followed by
sequencing of the corresponding gene. In addition, false-
negative results may occur when using techniques including
primers targeting the blaOxA-48-like gene in a variable region.
This report underlines that molecular diagnostic techniques
in the current phase of their development should not be
considered as reference standards for the detection of CRE
carriers. Those molecular-based techniques may detect only a
limited number of known genes. They should be reserved for
rapid identiﬁcation of carriers during management of outbreaks
when the index case has been identiﬁed.
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TABLE 1. Results of antimicrobial susceptibilities and carbapenemase genes carriage of the three carbapenem-resistant Escherichia
coli
Strain
Antimicrobial
susceptibilitya Antimicrobial resistancea
Carbapenem MICs and
susceptibilitya
Carba
NP test
Carbapenemase
genes PCR screeningb Sequencing
Ecol1 Fox, Amk, Tob,
Gm, Sxt,
Amp, CoAmox-clav, Tic,
Tic-clav, Pip, Pip-taz, Ctx,
Caz, Fep, Ofx
Ertapenem: 0.75 mg/L (I)
Imipenem: 0.5 mg/L (S)
Meropenem: 0.25 mg/L (S)
Positive blaOxA-48 OXA-181
Ecol2 Fox, Amk, Tob,
Ofx
Amp, CoAmox-clav, Tic,
Tic-clav, Pip, Pip-taz, Ctx,
Caz, Fep, Gm, Sxt,
Ertapenem: 0.5 mg/L (S)
Imipenem: 0.5 mg/L (S)
Meropenem: 0.5 mg/L (S)
Positive blaOxA-48 OXA-181
Ecol3 Fox, Amk, Tob,
Gm, Ofx
Amp, CoAmox-clav, Tic,
Tic-clav, Pip, Pip-taz, Fox,
Ctx, Caz, Fep, Tob, Gm, Sxt
Ertapenem: 0.75 mg/L (I)
Imipenem: 0.5 mg/L(S)
Meropenem: 0.38 mg/L (S)
Positive blaOxA-48 OXA-181
aAbbreviations: Amp, ampicillin; CoAmox-clav, amoxicillin-clavulanate; Tic, Ticarcillin; Tic-clav, Ticarcillin-clavulanate acid; Pip, piperacillin; Pip-taz, Piperacillin-tazobactam; Fox,
cefoxitin; Ctx, cefotaxime; Caz, ceftazidime; Fep, Cefepime; Amik, Amikacin; Tob, tobramycin; Gm, gentamicin; Ofx, oﬂoxacin; Sxt, Trimethoprim-sulfamethoxazole; according to
EUCAST interpretation guidelines for clinical isolates [http://www.eucast.org].
bIncluding blaVIM, blaNDM, blaKPC and blaOxA-48.
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